Literature DB >> 9714420

Expression of GM-CSF receptor and "in vitro" effects of GM-CSF on human fibroblasts.

L Postiglione1, S Montagnani, A Riccio, P Ladogana, S Salzano, L Vallefuoco, G Rossi.   

Abstract

In the present study the effects of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) on fibroblast growth and activity have been studied. In this regard the AA have evaluated in primary cultures of human gengival normal fibroblasts (PG1 cells): a)-the expression of GM-CSF receptor (GM-CSFR) (alfa unit) on the cell surface; b)-the in vitro effects of different doses of GM-CSF on the GM-CSFR expression and on the proliferation and activity of fibroblasts. PG1 cells have been stimulated in vitro with different concentrations of GM-CSF (10, 50, 80, 100 and 150 ng/ml) using promonocytic cell line U937 as positive control for GM-CSFR expression. GM-CSFR was investigated by flow cytometry, with mouse monoclonal antibody (mAb) against the alfa chain of the human GM-CSFR and fluorescein-conjugated goat antimouse immunoglobulin G (IgG). At high GM-CSF concentration (80 ng/ml) the AA observed: 1)-A marked increase of GM-CSFR expression evaluated as fluorescence intensity (about three fold in respect to the controls); 2)-Maximal increase of PG1 cells proliferation. Moreover immunofluorescence on fibroblasts obtained from culture plates showed increased actin stress fibers and fibronectin production with low stimulation by GM-CSF, while higher concentration of this cytokine determined increased proliferation of cells, but a decreased formation of actine fibers and vinculin plaques. These results demonstrate: 1)-The presence of GM-CSFR on the surface of fibroblasts; 2)-The proliferation and the synthesis activity of these cells (in vitro) are modulated by different concentration of GM-CSF. We hypothesize that GM-CSF until 80 ng/ml can upregulate the expression of the receptor. Therefore, on the basis of previous findings of high serum levels of GM-CSF in course of scleroderma, a disease characterized by fibroblast hyperactivity, a possible role of this cytokine in the pathogenic process of this disease can be hypothesized.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714420     DOI: 10.1016/s0024-3205(98)00281-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.

Authors:  Mohit Sachdeva; Philippe Duchateau; Stéphane Depil; Laurent Poirot; Julien Valton
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

2.  Dose-dependent impairment of collagen deposition by topical granulocyte-macrophage colony-stimulating factor in human experimental wounds.

Authors:  Lars N Jorgensen; Magnus S Agren; Søren M Madsen; Finn Kallehave; Faranak Vossoughi; Annette Rasmussen; Finn Gottrup
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  Low concentrations of cytokines produced by allergen-stimulated peripheral blood mononuclear cells have potent effects on nasal polyp-derived fibroblasts.

Authors:  S Olsson; F Cagnoni; P Dignetti; G Melioli; G W Canonica
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

4.  Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism.

Authors:  Matthias Schürmann; Felix Oppel; Senyao Shao; Verena Volland-Thurn; Christian Kaltschmidt; Barbara Kaltschmidt; Lars-Uwe Scholtz; Holger Sudhoff
Journal:  Cell Commun Signal       Date:  2021-02-24       Impact factor: 5.712

5.  Synoviocytes from pigmented villonodular synovitis are less sensitive to cadmium-induced cell death than synoviocytes from rheumatoid arthritis.

Authors:  Héléna Farese; Mélissa Noack; Pierre Miossec
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.996

6.  Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice.

Authors:  Marcela Rosas; Siamon Gordon; Philip R Taylor
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.